Cherubism is an autosomal dominant disorder that may be related to tooth development and eruption. It is a disorder of age-related bone remodeling, mostly limited to the maxilla and the mandible, with loss of bone in the jaws and its replacement with large amounts of fibrous tissue. We have used a genomewide search with a three-generation family and have established linkage to chromosome 4p16. Three other families affected with cherubism were also genotyped and were mapped to the same locus. The combined LOD score is 4.21 at a recombination fraction of 0, and the locus spans an interval of ∼22 cM.
Introduction
Cherubism (CBM; MIM 11840) is characterized by a loss of bone, restricted to the jaws, and by the replacement of this bone with fibrous tissue. As first described by Jones (1933) , patients with CBM show symmetrical, hard, and painless swelling of the jaws in childhood. The involvement of the infraorbital rim and the orbital floor leads to the upward tilting of the eyeballs and consequent exposure of the inferior part of the sclerae. This gives the child a Љcherubic" look, like that in Renaissance portrayals of angels. Submandibular lymph-node enlargement is often reported. In addition to the aesthetic deformity and its psychological consequences, functional impairment includes mastication and speech problems (Faircloth et al. 1991) , tooth alterations, and loss of normal vision (Marck and Kudryk 1992) . The onset of the disease is usually at 14 mo-4 years of age. It progresses through puberty, then stabilizes and, remarkably, in some cases regresses without treatment (Katz et al. 1992; Timosca 1996) .
The characteristic radiographic findings in CBM are well-defined multilocular areas of diminished density, often very extensive, with a few irregular bony septa. In the adult, the multilocular rarefactions become replaced by sclerosis, with progressive calcification (Cornelius and McClendon 1969) .
No studies of the cellular and molecular basis for CBM are available. To understand the pathogenic mechanisms that are involved in the bone resorption and deposition of fibrous tissue in the jaws, we selected a genetic approach. As a basis for gene identification, we have determined the chromosomal locus for the cherubism gene. Here we describe clinical findings in a three-generation family affected with cherubism and in a genomewide search to find linkage. The linkage data were confirmed in three other families.
Subjects and Methods

Families
During the past 2 years, we have encountered 15 patients (10 males and 5 females) from four families with CBM. Families were referred by clinicians in Brazil and Germany (families A and D-Instituto de Cirurgia Plastica Craniofacial, SOBRAPAR, Brazil, Dr. Cassio M. Raposo do Amaral; family B-Universidade Federal do Rio Grande do Sul, Brazil, Dr. Francisco M. Salzano; family C-Universitä t zu Berlin, Institut fü r Medizinische Genetik, Dr. Hartmut Peters). The clinical investigators were responsible for explaining the research to the families and obtaining their informed consent, in accordance with their local institutional review boards. The study was approved by the Harvard Medical School and the Forsyth Dental Center review boards. Peripheral blood samples (3-5 ml) were collected and shipped to Boston.
Figure 1
Pedigree of family A affected with CBM. Haplotypes for each family member are listed below the pedigrees. The most likely haplotypes for the linked allele are indicated as boxed areas. The arrow indicates the proband II-22.
Figure 2
Proband of family A
Figure 3
Multilocular radiolucencies observed on ortopantomograph of proband
Genotyping
DNAs were isolated from the blood samples (Puregene; Gentra Systems) and polymorphic microsatellite markers (short-sequence-repeat polymorphisms [SSRPs]) were selected (Dib et al. 1996) and purchased from Research Genetics. PCR amplification of genomic DNA was performed in a 10-ml volume containing 10 ng of template DNA and 4 pmol of each primer. The forward primers were end-labeled with g[ 33 P]-ATP. Conditions for PCR included an initial denaturation step at 95ЊC for 4 min, followed by 29 cycles at 94ЊC for 40 s, 56ЊC for 50 s, 72ЊC for 50 s, with a final extension at 72ЊC for 10 min. PCR products were denatured at 95ЊC for 5 min in the presence of 40% formamide. Aliquots (2.5 ml) were separated on denaturing polyacrylamide gels; this was followed by autoradiography.
Linkage analysis
Pairwise linkage analysis between the disease locus and each of the marker loci, was performed by the MLINK program of the LINKAGE package (Lathrop et al. 1985) , under the assumptions of a disease-gene frequency of 0.1%, equal allele frequency, full penetrance, autosomal dominant inheritance, and equal recombination rates for males and females.
Histology
Samples of affected tissues were collected from the proband and were fixed in 4% paraformaldehyde in PBS for 24 h. The samples were washed and were immersed in 20% sucrose/PBS and were shipped to Boston. Decalcification was performed in 10% formic acid, which was changed every other day for 2 wk, on a shaker. The samples were dehydrated in two 30-min changes of 70% ethanol, followed by one 30-min change each of 90% and 95% ethanol. This was followed by three 30-min changes of 100% ethanol. The tissue was then immersed in three 30-min changes of xylene, followed by a 1:1 solution of xylene/wax, and was left overnight at 60ЊC. Subsequently, the tissue was immersed in three 1-h
Figure 4
Photomicrograph showing presence of multiple osteoclast-like cells within both cellular and fibrous tissue and bone fragment, in biopsy of maxilla of proband (II-22) of family A (#100).
changes of paraffin at 60ЊC, followed by embedding in paraffin. Sections (7 mm) were made and were stained with hematoxylin and eosin, were mounted in Permount, and were analyzed by light microscopy.
Results
Clinical Findings
The evaluation of the proband (patient II-22) led us to a three-generation family (family A), with eight affected individuals-four males and four females ( fig.  1 )-displaying the CBM phenotype. Individuals within the family were considered affected with CBM when they presented clinical history of enlargement of maxilla and/or mandible, with onset in childhood and/or radiographic evidence of multilocular radiolucencies in the jaws.
The proband, patient II-22 ( fig. 2 ) is a 14-year-old female with maxillary enlargement that started at age 5 years and has that has continued to date. The palatal vault is obliterated because of bone overgrowth. Radiographic multilocular radiolucencies ( fig. 3 ), enlarged submandibular lymph nodes, and numerous dental anomalies were noted on both clinical and radiographic examination. Histological analysis of lesion tissue showed the presence of multiple osteoclast-like cells in a fibrous and cellular stroma ( fig. 4) . Radiographs from the whole body failed to show any other bone alteration. A cytogenetic study did not show any chromosomal abnormalities. Both analysis of blood cells, proteins, and ions (including parathyroid hormone, calcitonin, and calcium) and coagulation tests failed to identify any abnormalities. Analysis of urinary constituents was also normal. These findings are all consistent with the diagnosis of cherubism.
For family A, the mandible in males was more severely affected than the maxilla, whereas in females the maxilla was more severely affected. On average, the clinical onset of the disease was earlier in females (5.5 years of age) than in males (10.6 years of age) (table 1).
Assignment of the CBM Gene to Chromosome 4p
We have mapped the locus for CBM by means of DNA from family A ( fig. 1 ). Traditional linkage analysis (Morton 1955; Dracopoli 1995) was first used to exclude several potential candidate gene loci. After excluding candidate-gene regions on chromosomes 6, 7, 9, 11, 12, 18, and 20, we switched to random mapping of the entire genome, using a set of 360 polymorphic microsatellite markers (Dib et al. 1996) separated by an average distance of 10 cM.
Under the assumption of full penetrance, simulation showed a maximum LOD score of 3.31 (recombination fraction [v] 0). The haplotype analysis showed no recombination on chromosome 4p, for markers D4S1614, D4S432, D4S3023, D4S2935, D4S3007, D4S394, D4S3009, D4S1582, and D4S2928. Maximum LOD scores (Z max ) were obtained for markers D4S1614, D4S432, and D4S2928 ( ). Z ϭ 3.31 max By the same approach and methods, three other families (families B-D) were also analyzed. Haplotypes for the three families showed no conflict with the data for family A, and the LOD scores were positive for all of them. The combined LOD score for pedigrees A-D is 4.21 ( ) (table 2) . The locus spans an interval of v ϭ 0 ∼22 cM, according to the Généthon human linkage map (Dib et al. 1996) .
Family B (fig. 5) has been described elsewhere (Salzano and Ebling 1966) 
Discussion
Linkage of the cherubism locus was assigned to chromosome 4p16 on the basis of data from family A. Haplotype-analysis data from families B-D are supportive of this linkage, although by themselves the LOD scores for these families (0.60, 0.30, and 0.30 respectively) would not be sufficient for assignment of linkage.
Affected members of the four families included in this study show, in most cases, the typical characteristics of CBM. However, our observations differ from previous reports with regard to sex differences in expressivity and to penetrance of the disorder. Variable expressivity is reported for CBM, with 100% penetrance in males and reduced penetrance in females-50%-70%- . In family A, however, reduced penetrance in females was not observed. In fact, the males of this family had a milder expression of the disease than was seen in the females. One of the affected males (II-12) was diagnosed as affected on the basis of radiographic evidence only, and he had no physical signs of the disease.
For family A, the linkage data suggest that the locus spans the interval between markers D4S2936 and D4S2949. A critical individual in this family is the child III-105. At this time, she is 2.5 years old, with no clinical signs of the disease. Her radiographs show some dental abnormalities that may not be related to the disease, since her unaffected mother also presented with some dental anomalies. Another clinical finding in this child, however, was a preauricular appendage, a feature present in her 23-year-old affected uncle, family member II-21. The presence of a preauricular appendage has not been previously reported as a characteristic feature of CBM, but we cannot exclude the possibility that it is associated with CBM in this family. The child III-105 shows a breakpoint between markers D4S2936 and D4S1614. If we assume that she is not affected, then the locus is defined as being between markers D4S2936 and D4S2949. Recombinations in families B and D restrict the locus further, to an interval of ∼21 cM between markers D4S2936 and D4S1582. Should future analyses indicate that subject III-105 is affected, the locus for the CBM gene would be on the telomeric side of D4S2936.
At present, however, the most reasonable conclusion from the linkage data on all four families is that the locus for CBM is located on the telomeric side of D4S1582. A total of 1.65 Mb from 4p16 has been sequenced in the course of identification of the Huntington disease gene (Zuo et al. 1993) . Many disorders-such as achondroplasia (MIM 100800; Shiang et al. 1994 ; 
Figure 5
Pedigrees of families B (A), C (B), and D (C) affected with CBM. Haplotypes for each available family member are listed below the pedigree. Boxed areas indicate the most likely alleles. Rousseau et al. 1994) , hypochondroplasia (MIM 146000; Bellus et al. 1995; Stoilov et al. 1995) and Crouzon syndrome (MIM 123500) with acanthosis nigricans (Meyers et al. 1995) -are all caused by mutations in the FGFR3 gene that map to chromosome 4p16. Both congenital stationary type 3 nightblindness (Gal et al. 1994 ) and a subset of recessive retinitis pigmentosa (McLaughin et al. 1993 ) are caused by mutations in PDE6B (MIM 180072), the most telomeric gene described on chromosome 4.
According to Jones (1965) , typical cases of cherubism do not involve bones other than the maxilla and mandible. A few reports describe signs in other bones, such as rarefaction or cystlike changes in the ribs (Wayman 1978) and the humerus (Thompson 1962 ). In the families described here, however, we did not find any evidence of other bones being affected. Radiographic exams of the whole body were performed for the proband of family A, and no alterations were detected in other bones. We conclude, therefore, that CBM in the families that we studied is a localized disorder restricted to the jaws. Considering that the bones of the jaws house the developing teeth, one interesting possibility is that the disorder may be related to the development of the permanent dentition (Jones 1965) .
In patients with CBM, teeth may be displaced, unerupted, unformed, or absent or may appear to be floating in cystlike spaces. Malocclusion, premature exfoliation of deciduous teeth, and root resorption have also been reported . The disease does not seem to be an early developmental disorder, since children are born with no signs of the disease and usually do not express any symptoms until several years after birth. The disease develops in a time frame coinciding with many different events of tooth development, particularly the eruption of the permanent dentition, and the most dramatic expression of the disorder is seen at age 5-15 years. Therefore, the tooth abnormalities may indeed be related to the genetic causes of cherubism. In family A, agenesis of teeth was present in two severely affected females.
CBM has been reported in association with mosaicism for both expansion and deletion of the FMR1 gene, with clinical symptoms of mental retardation, prominent forehead, and macroorchidism (Quan et al. 1995) . Association of CBM with Noonan syndrome has also been reported (MIM 163955; Dunlap et al. 1989) . But finding the locus for CBM on chromosome 4 confirms a suggestion by Cohen and Gorlin (1991) that these disorders are indeed different entities, since Noonan syndrome has been mapped to chromosome 12 (Jamieson et al. 1994) . CBM, in association with gingival fibromatosis, has been given the designation "Ramon syndrome" (MIM 266270; Ramon et al. 1967) . One family has been described with Ramon syndrome and juvenile rheumatoid arthritis (de Pina-Neto et al. 1986 . Ramon syndrome has not yet been mapped, and it will be interesting to test for linkage to the CBM locus.
Bone homeostasis reflects the balance between bone formation by osteoblasts and bone resorption by osteoclasts. In CBM there is excessive bone resorption restricted to the maxilla and mandible. Physical contact with osteoblasts or marrow stromal cells is required for osteoclast differentiation, and recent findings have led to the identification of what are likely to be the molecular mediators of this contact-dependent process. RANK, a cell-surface receptor on osteoclast-progenitor cells (Anderson et al. 1997) , interacts with RANKL/TRANCE, which appears to be identical to an osteoblast/stromal cell-associated factor called "osteoclast differentiation factor" (ODF) (Wong et al. 1997; Yasuda et al. 1998) . A soluble factor called "osteoclastogenesis-inhibitory factor" (OCIF), with homology to osteoprotegerin (OPG), can block the interaction between RANK and RANKL, thereby inhibiting osteoclast differentiation (Simonet et al. 1997) . In CBM, localized down-regulation of a factor such as OPG could account for the increase in osteoclast differentiation and could cause excessive bone resorption in the maxilla and mandible.
The mutation causing CBM could be a factor involved in the regulation of any of the genes regulating bone formation or resorption, including CBFA1 (Mundlos et al. 1997) , RANK (Anderson et al. 1997) , RANKL/ TRANCE/ODF (Wong et al. 1997; Yasuda et al. 1998) and OPG/OCIF (Simonet et al. 1997) . However, none of these genes implicated in osteoblast and osteoclast differentiation/function are mapped to chromosome 4p. It is likely, therefore, that identifying the gene for CBM will provide novel insights into bone homeostasis. It may also have therapeutic consequences. At present there is no rational treatment for CBM. In severe cases, when there is functional and aesthetic impairment, surgical intervention is necessary (Kaugars et al. 1992) . Thus, identification of the CBM gene not only should contribute significantly to the understanding of bone resorption and formation in the mandible and maxilla but may also help in the design of an effective therapy.
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